tirzepatide estrogen Women taking hormone therapy lost 35% more weight on than women taking the drug alone. A Mayo Clinic study published in The Lancet this year — and most women on GLP-1s tirzepatide and progesterone Menopause as

Description

Study: TripleHormone Receptor Agonist Retatrutide for Obesity (Phase 2 Trial, NEJM) Drug: Retatrutide a triple agonist (GLP-1, GIP, and glucagon receptors) Key Findings: Up to 28.7% mean weight loss at higher doses Marked improvements in insulin sensitivity and cardiometabolic risk factors Weight loss approaching outcomes seen with bariatric surgery, without surgery What makes Retatrutide unique is its triple-hormone mechanism, simultaneously targeting appetite regulation, energy expenditure, and glucose metabolism

MyGLP-1 Sugar Defense is a next-generation metabolic support formula designed to help manage post-meal blood sugar, promote healthy GLP-1 levels, and support natural appetite control every time you eat.* At the core is Reducose, a patented white mulberry leaf extract clinically shown to reduce post-meal glucose sp

$58B GLP-1 Weight Loss Showdown The GLP-1 market is turning into a high-stakes battle between two pharmaceutical giants: Novo Nordisk Wegovy & Ozempic Eli Lilly Zepbound & Mounjaro Key points: Explosive growth:Already exceeding $58 billion in market size and accelerating rapidly

The pharmaceutical giant sued Strive and several other compounders for distributing products containing tirzepatide, the primary ingredient in Lilly's GLP-1 weight-loss and diabetes medications.